Achieve Life Sciences’ (ACHV) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Achieve Life Sciences (NASDAQ:ACHV) in a research report released on Wednesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also commented on ACHV. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. Citizens Jmp assumed coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price objective for the company. Finally, Citigroup started coverage on shares of Achieve Life Sciences in a report on Tuesday, November 25th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Achieve Life Sciences presently has an average rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Stock Down 2.8%

ACHV opened at $2.82 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $6.03. The stock has a market capitalization of $150.11 million, a P/E ratio of -2.17 and a beta of 1.81. The business has a 50 day simple moving average of $4.43 and a 200-day simple moving average of $4.30.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). On average, equities analysts anticipate that Achieve Life Sciences will post -1.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. lifted its position in Achieve Life Sciences by 18,747.4% during the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after buying an additional 4,346,011 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $2,652,000. Millennium Management LLC raised its stake in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock valued at $6,755,000 after acquiring an additional 1,121,614 shares during the period. Pathstone Holdings LLC acquired a new position in shares of Achieve Life Sciences during the 3rd quarter valued at $1,581,000. Finally, KVP Capital Advisors LP acquired a new position in shares of Achieve Life Sciences during the 4th quarter valued at $2,298,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $12.00 price target (~325% upside from current levels), providing a strong bullish analyst catalyst that could support buying interest. Read More.
• Positive Sentiment: Achieve announced a manufacturing partnership with U.S.-based Adare Pharma Solutions for cytisinicline — this addresses supply chain/CMC risk and is a practical step toward commercialization if clinical/regulatory progress continues. Read More.
• Positive Sentiment: Unusual options activity: a large spike in call buying (≈2,079 calls, ~175% above average) suggests some traders are positioning for upside or event-driven moves. (No direct article link available in feed.)
• Neutral Sentiment: Q4 / FY2025 results and conference call: revenue/operational updates were provided and management reiterated program plans; EPS missed consensus by $0.01 (reported ($0.28) vs. ($0.27) est.) — not a major beat/miss but worth watching for forward guidance. Read More.
• Neutral Sentiment: Full earnings call transcript and coverage are available for detail review — investors should listen for timeline and regulatory strategy comments that could move the stock. Read More.
• Neutral Sentiment: Short-interest entries in the feed report a “significant increase” but show zero shares / NaN changes — data appears inconsistent or erroneous, so treat these items cautiously until official NASDAQ/FINRA data is confirmed. (No reliable link provided.)
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims involving Achieve executives — this introduces legal/regulatory risk and could pressure sentiment if it develops further. Read More.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.